Yüklüyor......
New emerging targets in cancer immunotherapy: the role of LAG3
The success of immunotherapy in many disease entities is limited to a specific subpopulation of patients. To overcome this problem, dual blockade treatments mainly against cytotoxic T-lymphocyte-associated protein 4 (CTLA4) and programmed cell death receptor (ligand) 1 (PD-(L)1) axis were developed....
Kaydedildi:
| Yayımlandı: | ESMO Open |
|---|---|
| Asıl Yazarlar: | , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
BMJ Publishing Group
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6555869/ https://ncbi.nlm.nih.gov/pubmed/31231559 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2018-000482 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|